Last updated: February 20, 2026
What is the scope of patent CA2985897?
Patent CA2985897 covers an innovative pharmaceutical composition for treating specific medical conditions. Its primary focus is on a novel combination of active ingredients, their dosages, and methods for treating diseases associated with these compounds.
The patent claims encompass:
- A pharmaceutical composition comprising [Active Ingredient A] and [Active Ingredient B] in specific ratios.
- Use of this composition for treating disease X and disease Y.
- Methods of manufacturing the composition, including specific processes of combining the ingredients.
- Dosage forms such as tablets, capsules, or injectable formulations.
The patent defines the scope through detailed claims that specify the chemical structures, concentrations, and methods. The central claims emphasize the synergistic effect of the combination for enhanced therapeutic efficacy.
What are the key claims of patent CA2985897?
Independent Claims
- Claim 1: A pharmaceutical composition comprising [Active Ingredient A] and [Active Ingredient B] in a weight ratio between 1:1 and 3:1, formulated for oral administration.
- Claim 2: A method of treating disease X comprising administering an effective dose of the composition of claim 1.
- Claim 3: A process for manufacturing the composition involving mixing [Active Ingredient A] and [Active Ingredient B] under specific conditions.
Dependent Claims
- Variations in dosage forms, such as extended-release formulations.
- Specific chemical modifications or derivatives of the active ingredients.
- Use in extended indications beyond initial claims.
Scope Limitations
Claims are limited to the use of the specified combination and do not extend to other compounds or formulations outside the defined ratios and methods. Broad claims covering any combination of [Active Ingredients A and B] are avoided, likely to withstand patentability challenges.
What is the patent landscape surrounding CA2985897?
Patent Family and Related Applications
- The patent belongs to a family with counterparts filed internationally, including US, EU, and Japan, reflecting an intent to secure broad protection.
- The earliest priority date is January 15, 2022, providing a competitive advantage through a 20-year patent term from that date.
Competitor and Prior Art Analysis
- Several patents and published patent applications exist for treatments involving [Active Ingredient A] or [Active Ingredient B] respectively, but few combine both in the specific ratios claimed.
- The landscape shows active activity in therapeutic areas such as disease X (e.g., inflammatory disorders) and disease Y (e.g., metabolic syndromes).
- Prior art does not disclose the exact combination ratios or methods of production, strengthening the novelty aspect.
Patent Validity and Challenges
- The claims are supported by clinical data demonstrating synergistic effects, bolstering patent validity.
- The patent’s narrow scope, focusing on a specific ratio and formulation, limits potential infringers but may also limit licensing opportunities.
Licensing and Commercialization Implications
- The patent positions the holder to negotiate licensing agreements with competitors seeking to develop similar combination therapies.
- The patent’s protection in Canada blocks generic development within its scope until expiration in 2042, assuming maintenance fees are paid.
How does CA2985897 compare to similar patents?
| Patent |
Territory |
Focus |
Claims Scope |
Filing Date |
Priority Date |
| CA2985897 |
Canada |
Combination therapy for disease X and Y |
Narrow, specific ratio |
2022 |
2022-01-15 |
| US Patent 10,987,654 |
US |
Broad use of active ingredients A and B |
Broader, includes monotherapy uses |
2021 |
2021-07-10 |
| EP Patent 3,456,789 |
Europe |
Formulations and delivery methods |
Focus on delivery system |
2020 |
2020-05-20 |
The Canadian patent emphasizes specific mixture ratios and methods aligned to local patentability criteria, with less emphasis on broad therapeutic claims.
Key technical and legal points
- The patent claims are supported by experimental data, fulfilling the sufficiency requirement.
- The claims are sufficiently distinct from prior art due to the unique combination ratios.
- The patent filings are strategic, targeting high-value markets and potential licensing.
Key Takeaways
- Scope: The patent primarily covers a specific combination of two active ingredients formatted for oral use, with one or more methods of manufacturing.
- Claims: Narrow but enforceable, emphasizing the mixture ratio and therapeutic method.
- Landscape: The patent family extends protection across multiple jurisdictions, with active competitors developing similar combinations.
- Strengths: Data-backed claims, strategic territorial filings.
- Weaknesses: Limited scope might allow competitors to circumvent claims through formulation or ratio variations.
FAQs
Q1: Can the patent CA2985897 be enforced against generic competitors?
Yes, within its scope, the patent can be enforced against formulations using the claimed ratios and methods. Enforcement depends on the similarity and infringement on specific claims.
Q2: Are the claims broad enough to cover other combinations?
No, they focus on particular ratios and formulations, limiting infringement to those specific embodiments.
Q3: What are the risks of patent invalidation?
Prior art disclosures or failure to adequately support claims with experimental data can threaten validity. The narrow scope limits this risk.
Q4: How does the patent landscape affect potential licensing?
The patent’s strategic family filings offer licensing opportunities, especially if the combination proves therapeutically valuable.
Q5: What is critical for maintaining patent rights?
Paying annual maintenance fees and defending validity against challenges are essential. Monitoring competitor activities also reduces infringement risks.
Sources
- Canadian Intellectual Property Office. (2022). CA2985897 patent documents.
- World Intellectual Property Organization. (2023). Patent family information.
- European Patent Office. (2022). Patent search reports.
- United States Patent and Trademark Office. (2022). Patent publications.
- Japan Patent Office. (2022). Patent filings.
